Livagen
Lys-Glu-Asp-Ala tetrapeptide (KEDA)
No human clinical trials have been conducted. All evidence comes from animal or laboratory studies.
A synthetic short peptide studied mainly in laboratory experiments with elderly human immune cells and animal liver tissue, where it appears to reactivate genes that had been switched off during aging. No human clinical trials have been conducted, so its safety and effectiveness in people are unknown.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Livagen is preclinical or hypothesis-only.
No human clinical trials have been conducted. All evidence comes from animal or laboratory studies.
Safety Summary
No peer-reviewed safety data, dedicated toxicology studies, FDA labels, or FAERS case records exist for Livagen. All side effect information above comes from vendor pages and community anecdotes, which are not substitutes for clinical pharmacovigilance. Peptide Initiative reports adverse events in less than 5% of patients from Eastern European clinical use spanning 20+ years, but this claim could not be verified against primary clinical data. Preclinical rodent studies reportedly showed no observable toxic effects at low-to-moderate doses with repeated dosing for up to 30 days. One online communities user reported severe anxiety and cardiac palpitations lasting several months after a 12-day protocol. No data on drug-drug interactions, pharmacokinetics, or carcinogenic risk exists. The absence of carcinogenicity or mutagenicity data is a notable gap given that the peptide's mechanism involves chromatin remodeling which could theoretically unmask oncogenes.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 20 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 11713572PubMed
- 2PMID 12096446PubMed
- 3PMID 12533768PubMed
- 4PMID 12577697PubMed
- 5PMID 12942748PubMed
- 6PMID 15085253PubMed
- 7PMID 15926314PubMed
- 8PMID 16075683PubMed
- 9PMID 16705247PubMed
- 10PMID 17460203PubMed
- 11PMID 17921545PubMed
- 12PMID 18830022PubMed
- 13PMID 20480236PubMed
- 14PMID 24423684PubMed
- 15PMID 25341254PubMed
- 16PMID 25541832PubMed
- 17PMID 28574395PubMed
- 18PMID 32362099PubMed
- 19PMID 35887081PubMed
- 20PMID 37042594PubMed